argenx Reports First Quarter 2026 Financial Results and Provides Business Update
argenx SE announced robust first quarter 2026 financial results, including $1.3 billion in global product net sales, a 63% year-over-year increase driven by strong adoption of its FcRn blocker VYVGART. The company highlighted upcoming FDA decision on label expansion for seronegative myasthenia gravis (PDUFA May 10, 2026) and multiple pipeline advan…